Prostate Cancer

Michael J. Morris, MD, discusses the results of the VISION trial of 177-lutetium-PSMA-61 in patients with metastatic castration-resistant prostate cancer.

Before closing out their discussion on metastatic CSPC, expert oncologists consider how best to educate patients and address the remaining unmet needs in this setting.

After reviewing data from the ARASENS trial, experts consider the role of the daralutamide-containing triplet regimen in metastatic CSPC.

During a Targeted Oncology case-based roundtable event, Sheela Tejwani, MD, discussed therapy options for a patient with metastatic castration-sensitive prostate cancer.

Adam Weiner, MD, discusses the importance of molecular testing for prostate cancer and what the current targeted therapy landscape looks like for this disease.

During a live virtual event, Roby A. Thomas, MD, discussed the choice of therapy for a patient with metastatic castration-sensitive prostate cancer.

Dr Tanya Dorff presents the case of a 72-year-old man with metastatic hormone-sensitive prostate cancer.

A review of data from the ALSYMPCA clinical trial on the use of radium-223 for prostate cancer treatment.

Key opinion leaders review the case of a 72-year-old man with metastatic CSPC and consider optimal treatment approaches in this setting.

Comprehensive insight on darolutamide therapy in nonmetastatic CRPC, supported by clinical data from the ARAMIS trial.

In the interview, Mark Markowski, MD, discussed how the findings from the phase 1/2 trial of sabizabulin in patients with metastatic castration-resistant prostate cancer this may influence future research with the oral agent.

Shared insight on how expert oncologists select therapy for patients with nonmetastatic castration-resistant prostate cancer.

Expert perspectives on optimal patient follow-up, with particular regard for PSMA imaging, in nonmetastatic castration-resistant prostate cancer.

A discussion on the use of lutetium-PSMA-617 for prostate cancer treatment.

Experts in genitourinary oncology present data from the VISION clinical trial, studying patients with PSMA-positive metastatic castration-resistant prostate cancer.

Neal Shore, MD, FACS, discusses the purpose behind investigating enzalutamide in a cohort of patients with metastatic hormone-sensitive prostate cancer who were previously treated with local therapy as a post-hoc analysis of the ARCHES study.

During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the VISION trial supporting the use of 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles from this event.

Returning to the patient case, experts review available frontline treatment options in the setting of nonmetastatic castration-resistant prostate cancer.

A brief review of the prevalence of familial risk and other high-risk factors for prostate cancer, followed by recommendations for patient follow-up and genetic testing.

Dr Ulka Vaishampayan presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.

Phillip J. Koo, MD, provides a detailed explanation of the process of PSMA-PET imaging scans for prostate cancer.

Panelists center their discussion on a real-world patient case of nonmetastatic castration-resistant prostate cancer managed with surgery and adjuvant therapy.

Experts provide comprehensive insight on prostate cancer, covering its prevalence, subtypes, and the systemic treatment armamentarium.

Mark T. Fleming, MD, discusses the potential impact of positive data from the phase 3 SPOTLIGHT study, which assessed the how 18F-rhPSMA-7.3 PET scan use in male patients with biochemical recurrence of prostate cancer affects upstaging in comparison with conventional imaging.

In an interview with Targeted Oncology, Adam Weiner, MD, discussed molecular subtyping for prostate cancer based on basal and luminal cell-of-origin and how such research may impact the future of this space.

Mark Markowski, MD, PhD, discusses the design of a phase 1B/2 study of sabizabulin in men with metastatic castration-resistant prostate cancer who have had treatment and progression on an androgen receptor–targeting agent.

During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the results of the CARD trial of cabazitaxel for patients with metastatic castration-resistant prostate cancer. This is part 1 of 2 articles based on this event.

Tanya Dorff, MD, reviews guidelines for initial risk stratification of patients with localized prostate cancer, and the choices in imaging strategies.

According to the phase 3 ATLAS trial, radiotherapy can be administered with next-generation hormonal therapy in phase 3 trials of patients with high-risk localized or locally advanced prostate cancer.

Reduced risk of metastatic progression and improved overall survival seen with darolutamide in patients with nonmetastatic castration-resistant prostate cancer.